An analysis of Russian-produced clinical practice guidelines using the RIGHT reporting checklist: The case of direct oral anticoagulants for coronavirus disease 2019

Abstract

Objective

The objective of the study was to compare the results of quality assessment of Russian-produced clinical practice guidelines on the use of direct oral anticoagulants in the treatment and prophylaxis of coronavirus disease 2019 using the RIGHT checklist and AGREE II instrument.

Methods

We assessed six relevant clinical practice guidelines published between 2020 and 2023 in Russian databases using the RIGHT checklist. We compared the results of using the RIGHT tool with the results obtained using the AGREE II instrument.

Results

All six clinical guidelines received high scores in the sections “Basic information” (range: 56.2%–70.8%) and “Background” (48.4%–74.0%). The lowest results were obtained in the sections on RIGHT: “Review and quality assurance” (0%–4.2%) and “Funding and declaration management of interests” (14.6%–19.8%).

Conclusion

The RIGHT checklist was proven applicable and usable for evaluating Russian-produced clinical practice guidelines. The use of RIGHT reporting tool enriched the depth and breadth of quality assessment to identify more areas that are problematic and to critically appraise details of the problems. More efforts are needed to further improve Russian clinical practice guidelines and their implementation into clinical practice to ensure better patient care and rational use of direct oral anticoagulants.